Last reviewed · How we verify
GSK208141 vaccine
GSK208141 is a therapeutic vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.
GSK208141 is a therapeutic vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens. Used for Cancer immunotherapy (specific indication under investigation in phase 3).
At a glance
| Generic name | GSK208141 vaccine |
|---|---|
| Also known as | Herpes simplex vaccine |
| Sponsor | GlaxoSmithKline |
| Drug class | Therapeutic cancer vaccine |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As a therapeutic cancer vaccine, GSK208141 works by priming T cells and other immune effectors to target malignant cells. The vaccine formulation likely contains tumor-associated peptide antigens combined with an immunological adjuvant to enhance immune activation and durability of the anti-tumor response.
Approved indications
- Cancer immunotherapy (specific indication under investigation in phase 3)
Common side effects
- Injection site reactions
- Fatigue
- Fever
- Myalgia
Key clinical trials
- Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old (PHASE3)
- Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults (PHASE1)
- Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine (PHASE3)
- Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease (PHASE3)
- Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects (PHASE3)
- Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines (PHASE1, PHASE2)
- Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK208141 vaccine CI brief — competitive landscape report
- GSK208141 vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI